Screener
R&D at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Hemab Therapeutics Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Hemab Therapeutics Holdings, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344533
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses | ||||
| Research and development | $20,336 | $12,874 | $39,797 | $26,975 |
| General and administrative | 5,743 | 3,183 | 9,894 | 5,642 |
| Total operating expenses | 26,079 | 16,057 | 49,691 | 32,617 |
| Loss from operations | (26,079) | (16,057) | (49,691) | (32,617) |
| Other income (expense), net | ||||
| Interest income | 2,858 | 335 | 4,077 | 808 |
| Other (expense) income, net | (832) | 3,517 | (1,114) | 4,108 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Hemab Therapeutics Holdings, Inc.'s R&D?
- Hemab Therapeutics Holdings, Inc. (COAG) reported R&D of $20.34M in Q2 2026.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Hemab Therapeutics Holdings, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude